<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788176</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446HBR10T</org_study_id>
    <nct_id>NCT01788176</nct_id>
  </id_info>
  <brief_title>The Use of Zoledronic Acid to Complex Regional Pain Syndrome</brief_title>
  <acronym>Aclasta</acronym>
  <official_title>Phase 2 Study - The Use of a Single 5 mg Dose of Zoledronic Acid in Complex Regional Pain Syndrome Patient.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and the safety of using a single, intravenous 5mg dose of zoledronic&#xD;
      acid in managing pain in Complex Regional Pain Syndrome patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complex regional pain syndrome (CRPS) is a disorder of the extremities that is characterized&#xD;
      by spontaneous unexplained disproportionate pain, hyperalgesia, swelling, limited range of&#xD;
      motion, vasomotor instability, skin changes, and patchy bone demineralization.The incidence&#xD;
      of CRPS was estimated to be 5.46 per 100,000 person years at risk in Olmsted County,&#xD;
      Minnesota (US), with a prevalence of 20.57 per 100,000, while its incidence in the general&#xD;
      population of the Netherlands was estimated to be much higher, at 26.2 per 100,000&#xD;
      person-years. The adverse effects were not serious and lasted just a few days. The beneficial&#xD;
      effects of other bisphosphonates have been already documented in several placebo-controlled&#xD;
      trials; however, there are no reports on the use of zoledronic acid to reduce pain in CRPS&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain measured on Visual Analog Scale</measure>
    <time_frame>up to 12 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lower Limbs vertical force on Wii platform</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Orthopaedic Foot and Ankle Scale (AOFAS)</measure>
    <time_frame>Baseline, 3, 6 and 12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short Form Health Survey (SF-36)</measure>
    <time_frame>Baseline, 3, 6 and 12 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Complex Regional Pain Syndromes</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One single intravenous infusion of 100ml of saline (placebo control group).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one single dose of 5mg intravenous infusion of zoledronic acid (interventional group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)</description>
    <arm_group_label>Zoledronic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one single intravenous infusion of 100ml of saline.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients over 18 years of age of both genders, with continuing pain that is&#xD;
             disproportionate to any inciting event, with cardinal features of CRPS.&#xD;
&#xD;
          2. Pain - after initial injury with signs and symptoms present at first visit&#xD;
&#xD;
          3. History of previous unsuccessful treatment for pain, with a minimum of two drug&#xD;
             therapies, such as non steroidal anti-inflammatory drugs, steroids, antidepressants,&#xD;
             central acting analgesics, calcitonin or sympathetic blocks, (not bisphosphonates) for&#xD;
             at least six months.&#xD;
&#xD;
          4. Must report at least one symptom in three of the four following categories:&#xD;
&#xD;
               1. Sensory: Reports of hyperesthesia and/or allodynia&#xD;
&#xD;
               2. Vasomotor: Reports of temperature asymmetry and/or skin color changes and/or skin&#xD;
                  color asymmetry&#xD;
&#xD;
               3. Sudomotor/Edema: Reports of edema and/or sweating changes and/or sweating&#xD;
                  asymmetry&#xD;
&#xD;
               4. Motor/Trophic: Reports of decreased range of motion and/or motor dysfunction&#xD;
                  (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin).&#xD;
&#xD;
          5. Must display at least one sign* at time of evaluation in two or more of the following&#xD;
             categories:&#xD;
&#xD;
               1. Sensory: Evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch&#xD;
                  and/or deep somatic pressure and/or joint movement)&#xD;
&#xD;
               2. Vasomotor: Evidence of temperature asymmetry and/or skin color changes and/or&#xD;
                  asymmetry&#xD;
&#xD;
               3. Sudomotor/Edema: Evidence of edema and/or sweating changes and/or sweating&#xD;
                  asymmetry&#xD;
&#xD;
               4. Motor/Trophic: Evidence of decreased range of motion and/or motor dysfunction&#xD;
                  (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin).&#xD;
&#xD;
          6. Skin temperature of the affected side equal or higher than on the non-affected side.&#xD;
&#xD;
          7. No other diagnosis better explains the signs and symptoms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of systemic diseases including diabetes mellitus, hyperthyroidism, renal and&#xD;
             liver dysfunction, peripheral vascular or cardiovascular diseases, uncontrolled&#xD;
             hypertension, rheumatoid and hematopoietic diseases, neurological diseases not related&#xD;
             to CRPS, overt alcohol addiction, positive pregnancy test and/or lactating women,&#xD;
             hyperparathyroidism, and hypocalcaemia.&#xD;
&#xD;
          2. Creatinine clearance &lt;35mL/min, with serum creatinine measured before the dose of&#xD;
             zoledronic acid.&#xD;
&#xD;
          3. Pre-existing hypocalcaemia and disturbance of mineral metabolism (e.g.&#xD;
             hyperparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes,&#xD;
             and excision of small intestine).&#xD;
&#xD;
          4. Hypersensitivity to zoledronic acid or any component drugs used in the trial.&#xD;
&#xD;
          5. Patients with asthma and aspirin-sensitivity&#xD;
&#xD;
          6. Pregnancy or unwillingness to use contraceptive methods during the trial&#xD;
&#xD;
          7. Patients who have previously used any kind of bisphosphonate, especially zoledronic&#xD;
             acid.&#xD;
&#xD;
          8. Osteoporosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linamara R. Battistella, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Centro de Pesquisa Clínica do Instituto de Medicina Física e de Reabilitação do Hospital das Clínicas da FMUSP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Perola Grinberg Plapler, MD</last_name>
    <phone>55 11 39058512</phone>
    <email>perolagp@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marta Imamura, MD</last_name>
    <phone>55 11 39058512</phone>
    <email>martimf3@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica do Instituto de Medicina e Reabilitação do HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05716-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Pérola G Plapler, MDPhD</last_name>
      <phone>55 11 39058512</phone>
      <email>perolagp@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Marta Imamura, MDPhD</last_name>
      <phone>55 11 39058512</phone>
      <email>martaimf3@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pérola G. Plapler, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>October 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Pérola Grinberg Plapler</investigator_full_name>
    <investigator_title>MD, PhD, Director of Physical Medicine Division Of Institute Orthopedics and Traumatology of University of Sao Paulo General Hospital</investigator_title>
  </responsible_party>
  <keyword>Complex Regional Pain Syndromes</keyword>
  <keyword>drug therapy</keyword>
  <keyword>zoledronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

